Challenges and opportunities in continuous bioprocessing of lentiviral vectors and adeno-associated viral vectors.

Continuous bioprocessing significantly boosts yields and reduces costs in manufacturing AAV and LV vectors for gene therapy, with improvements up to 50% in efficiency.

• Why it matters: Scaling up viral vector production is essential for widespread gene therapy adoption, but current batch processes are costly and time-consuming, limiting accessibility.
• What they did: The review analyzes recent advances in upstream and downstream continuous bioprocessing, including transient transfection, stable cell lines, and innovative filtration and chromatography techniques.
• The result: Implementing continuous bioprocessing enables more efficient, cost-effective production, paving the way for broader clinical application and improved patient access to gene therapies.